Pfizer Secures Up to $1.5B in Blackstone Obesity Drug Co-Funding
Article excerpt
Highlighted: the sentence this signal was extracted from
Pfizer and Blackstone Life Sciences announced a strategic co-funding agreement on November 11, 2026, under which Blackstone-managed funds will pay up to $1.5 billion of development costs through 2028 for berobenatide, an investigational monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will be eligible for milestone-based payments tied to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management and the achievement of certain commercial sales milestones. Any milestone payments earned will be payable over a multi-year period. The structure ties Blackstone's compensation to both regulatory and commercial progress. Blackstone does not acquire any rights or ownership in berobenatide under the agreement, and Pfizer retains full operational control and decision-making for the program. Pfizer therefore gains an external source of development funding while continuing to direct the clinical work. The distinction separates the financing from ownership of the underlying medicine. Blackstone's claim is to conditional milestone payments, while Pfizer keeps authority over how the development program is conducted. Pfizer ( PFE ) plans to advance more than 20 trials for obesity and related comorbidities in 2026. The plan includes 10...
Keep reading with a free account
The rest of this article, and every signal for Pfizer, is in your free account.
